Eli Lilly (LLY) Offering Possible 25% Return Over the Next 21 Calendar Days

view original post

Eli Lilly’s most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $290.00 short call and a strike $295.00 long call offers a potential 25% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $290.00 by expiration. The full premium credit of $1.00 would be kept by the premium seller. The risk of $4.00 would be incurred if the stock rose above the $295.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.

The RSI indicator is at 29.21 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Eli Lilly

Eli Lilly Beats Estimates and the Stock Jumps on Revenue Guidance Boost
Thu, 28 Apr 2022 11:26:00 +0000
Shares of Eli Lilly made a strong move higher in premarket trading Thursday after the drugmaker reported first-quarter earnings and sales that topped Wall Street estimates and boosted revenue guidance for the year. Analysts surveyed by FactSet expected Lilly (ticker: LLY) to earn $2.29 a share in the quarter on sales of $7.3 billion. Eli Lilly raised its sales forecast for 2022 to $28.8 billion to $29.3 billion, up from previous guidance of $27.8 billion to $28.3 billion.

Eli Lilly Stock Leaps As Trulicity Sales Drive Q1 Earnings Beat, Obesity Drug Trial Data
Thu, 28 Apr 2022 11:23:00 +0000
“We are well-positioned to help address health challenges in areas of significant unmet medical need, such as obesity, Alzheimer’s disease and cancer,” said CEO David Ricks.

Eli Lilly stock rallies after earnings beat expectations, as COVID-19 antibodies revenue jumps 81%
Thu, 28 Apr 2022 10:45:32 +0000
Shares of Eli Lilly & Co. rallied 1.8% in premarket trading Thursday after the drug maker reported first-quarter profit and revenue that beat expectations, as better-than-forecast COVID-19 antibodies results offset a Trulicity miss. Net income rose to $1.90 billion, or $2.10 a share, from $1.36 billion, or $1.49 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.62 was above the FactSet consensus of $2.29. Revenue grew 14.8% to $7.81 billion, beating

Solid First-Quarter Financial Results Reflect Lilly’s Continued Momentum into 2022
Thu, 28 Apr 2022 10:25:00 +0000
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2022.

Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Thu, 28 Apr 2022 10:15:00 +0000
Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company’s (NYSE: LLY) SURMOUNT-1 clinical trial, with participants losing up to 22.5% (52 lb. or 24 kg) of their body weight for the efficacy estimandi. This study enrolled 2,539 participants and was the first phase 3 global registration trial evaluating the efficacy and safety of tirzepatide in adults with obesity, or overweight with at least one como

Related Posts